Dicot Pharma
0.568
SEK
+14.4 %
Less than 1K followers
DICOT
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Ownership
Investor consensus
+14.4%
+76.4%
+106.92%
+134.23%
+154.71%
+201.09%
+220.23%
+3.02%
-77.77%
Dicot Pharma is developing the drug candidate LIB-01, which is expected to be a potency drug for the treatment of erectile dysfunction and premature ejaculation. Duration of action and fewer side effects are the main desired properties. Dicot's main strategy is to continuously evaluate industrial partnerships during the development of LIB-01 to take the drug candidate to commercialization.
Read moreMarket cap
1.14B SEK
Turnover
11.26M SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Financial calendar
11/8
2025
Interim report Q2'25
22/10
2025
Interim report Q3'25
All
Webcasts
Press releases
ShowingAll content types
Dicot Pharma AB: Dicot Pharma om nya fynd inom verkningsmekanismen: "påverkar nerverna som kontrollerar erektionen"
Dicot Pharma AB: Report from the Annual General Meeting of Dicot Pharma
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools